Novavax Analyzes Financial Performance and Debt Ratios

Novavax's financial assessment reveals critical metrics indicating challenges in its business quality and valuation. The company's Quality Rank, which evaluates balance sheet strength, profitability, and growth, suggests it is struggling relative to peers. As of October 2024, Novavax's enterprise value is €1,100.8 million, with an EV-to-EBITDA ratio of -5.24, reflecting significant losses over the trailing twelve months. Furthermore, its intrinsic value calculated via the Discounted Cash Flow model stands at €-8.71, indicating low predictability in its financial performance. The long-term debt to total assets ratio remains stable at 0.12, suggesting continued reliance on debt for operations. Overall, Novavax faces substantial financial hurdles as it develops its vaccine portfolio.